FIELD: biotechnology.
SUBSTANCE: present invention relates to immunology. Disclosed are versions of a human neutralizing anti-IL-33 monoclonal antibody, as well as a nucleic acid coding molecule, a vector, a host cell and a method of producing said antibody variants. Invention also discloses a composition for inhibiting expression of INF-gamma, IL-5, IL-6 or IL-13 cytokines, as well as a pharmaceutical composition for treating, preventing or ameliorating diseases associated with IL-33.
EFFECT: present invention can find further application in therapy, including inflammatory diseases.
15 cl, 11 dwg, 14 tbl, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
| THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
| gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
| IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
| METHODS OF TREATING PSORIASIS | 2008 |
|
RU2475265C2 |
| HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
| COMPOUNDS | 2007 |
|
RU2466139C2 |
